Cyclerion Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
245 First Street Riverview Ii Fl 18, Cam...Phone Number
(857) 327-8778Website
www.cyclerion.comRevenue
<$5 MillionStock Symbol
CYCNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.Explore more
Cyclerion Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyclerion Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cyclerion Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Cyclerion Therapeutics
Earning: See what the market has to say on Cyclerion Therapeutics recently announced quarterly report
Product Launch: Get notified when Cyclerion Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Cyclerion Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Cyclerion Therapeutics is spiking on competitors!
Click to see if Cyclerion Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cyclerion Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cyclerion Therapeutics
Compare insights from companies similar to Cyclerion Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cyclerion Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cyclerion Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cyclerion Therapeutics.
Cyclerion Therapeutics financials insights
Gather financial insights about Cyclerion Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$2M
Share Placement
$24M
Cyclerion Therapeutics Tech Stack
A closer look at the technologies used by Cyclerion Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Person-Based
Mergers & Acquisitions, Mergers
Project
Cyclerion Therapeutics has announced that its therapy for treatment-resistant depression is phase two ready, supported by three independent proof of concept trials that demonstrated encouraging signals. The company expects to initiate a proof of concept study by the end of 2026.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Cyclerion Therapeutics is developing a therapy for treatment-resistant depression that aims to be safe, highly efficacious, scalable, and efficient. The treatment is designed to offer rapid, durable relief without the burden of current therapy treatments, integrating into existing hospital infrastructure.
Medical Research, Pharmaceuticals, Healthcare Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Cyclerion Therapeutics News & Media
Alzheimer's biotech Korsana to go public via reverse merger - pharmaphorum
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer'sBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSE - NSA), Urgent.ly, Inc. (OTC Markets - ULYX), UniFirst Corporation (NYSE - UNF)
BALA CYNWYD, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Korsana. Click here to learn how to join our investigation and obtain additional...Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public - Fierce Biotech
After emerging from stealth last month with $175 million, Korsana Bioscie | After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyclerion Therapeutics
Sign Up For FreeTo access detailed company insights
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.... Read More
